TAAs aberrantly up-regulate in tumor tissue and ascites of ovarian cancer patients and include members of the cancer-testis antigen family (e.g. MAGE-A4 and NY-ESO-1), growth-activating receptors (e.g. HER2/neu), folate receptor alpha (FRα), p53, and CA125 [8-10]. Here, TP53 is linked to ovarian carcinoma.